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1. Introduction
Normal pregnancy is associated with complex changes of hemostasis, leading to hypercoa‐
gulability states. Such physiological increase of blood coagulation during pregnancy occurs
because of changes in the vascular endothelium and blood flow, generating changes from the
10th gestational week on. The changes may create a hypercoagulability state that results in
thrombosis. The purpose of the hypercoagulability state during pregnancy is to prevent
excessive bleeding by the time of delivery (Moreira, et al. 2008).
Normal hemostasis during pregnancy is the result of a balance between the system that
promotes blood coagulation and the one inhibiting excessive coagulation (fibrinolytic system).
Gestational effects on coagulation proteins may be detected after the 3rd month of pregnancy,
with significant changes in pro-coagulant proteins in comparison with physiological inhibi‐
tors. So, although changes in hemostatic system are intended for adaptation and protection of
the pregnant woman's body, they may cause increased risk of thromboembolic events.
Despite of being physiological, excessive activation of the coagulation mechanism during
pregnancy may lead to thromboembolic events, especially in women with hereditary and/or
acquired factors who have a known predisposition to thrombi formation.
Thrombophilia  is  a  hereditary  or  acquired  disease  related  to  changes  in  hemostasis
mechanisms  that  are  characterized  by  an  increased  trend  to  blood  coagulation  and
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consequent risk of thromboembolism (Machac S 2006). Hereditary factors that are consid‐
ered potentially responsible for such trend to thrombosis are: protein C deficiency, protein
S  deficiency,  anti-thrombin  deficiency,  presence  of  Factor  V  Leiden,  a  change  in  allele
prothrombin 20210 G>A gene and a change in the gene of enzyme methylenetetrahydrofo‐
late reductase (D’Amico 2006).
Thrombophilia hereditary causes have been researched since 1956, when Jordan and Nandorff
introduced the term thrombophilia. In 1965 anti-thrombin deficiency was identified as the
genetic cause of thrombophilia.
Such studies became larger in the 80’s, when protein S and protein C deficiencies were
described, as well as Factor V Leiden, in 1994. (Reistma PH 2007). Approximately 40% of
thrombosis cases showing arterial occlusion or venous occlusion are hereditary. Venous
thromboembolism frequently occurs as a result of several factors. Generally, thrombophilia
should be seen as a multi-factorial disorder, not as the expression of a single genetic change
(Buchholz T 2003).
The importance of angiogenesis for embryo implantation and the presence of thrombophilia
leading to micro-thrombosis at the implantation site with subsequent impairment of embryo
nidation and placental development should be considered as well (Vaquero E 2005).
The presence of thrombophilia was proven to be related to an increased risk of complica‐
tions during pregnancy, such as pre-eclampsia, intrauterine growth restriction, premature
detachment  of  placenta,  preterm  delivery,  recurrent  miscarriage,  chronic  fetal  distress,
besides ischemic events during pregnancy (Couto E 2005) (Ren A 2006) (Hoffman E 2012)
(Bennet SA 2012).
Events related to thrombophilic changes during pregnancy are shown below.
2. Thrombophilia and pregnancy
One of the most important discussions in clinical practice regards the indication to search for
a thrombophilic factor. This is due to elevated testing costs and its relevance to medical
management once diagnose is done.
Access to Internet and available information on practically all matters brings up questioning
by patients who look for these data regarding their personal risks and ask doctors how would
they have to behave. It is an important role for doctors to help patients to discriminate which
information are relevant for them, helping patient to pursue adequate options for personal
treatment and prophylaxis.
There has been a great deal of research relating thrombophilia to many clinical situations where
no scientific data is relevant. On the other side, there are still other clinical situations where
there is no consensus, or even there will not be a practical condition to define a medical practice,
based on studies performed up until now.
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Women are exposed to a great variety of factors that increase their risk of venous throm‐
boembolism (VTE) such as the use of hormonal contraception, pregnancy, puerperium and
hormonal replacement therapy for menopause.
The incidence of VTE is higher in woman during pregnancy and post partum when compared
to not pregnant women. There is an increase between five to ten times the risks of VTE, with
an incidence of 0.6 to 1.3 events for 1.000 deliveries (Heit JA 2005) (McColl MD 1997).
Although there are controversies whether the occurrence of VTE is greater during pregnancy
or post partum, it seems that this risk is equally distributed during all gestational period (Pomp
ER 2008). VTE is the most important cause of maternal death (Marik PE 2008).
Hereditary thrombophilia include Factor V Leiden (FVL), G20210A prothrombin gene
mutation, protein S, protein C and antithrombin III deficiency.
Prevalence of a hereditary thrombophilia is higher in women that had VTE during pregnancy,
especially FVL and G20210A gene mutation. In Japanese populations, protein S seems to be
the most common among pregnant women with VTE (Miyata T 2009).
Normal gestation is characterized by hypercoagulation, with increase of coagulation factors
II, VII, IX, X, XII, fibrinogen and Von Willebrand factor. There is a reduction in natural anti
coagulant factors, such as protein S, protein C and antithrombin III. There is also a reduction
in fibrinolysis caused by reduction in tissue plasminogen activating factor (t-PA) and increase
in the inhibitor of plasminogen activator (PAI-1). Increase of Factor VIII and reduction of
protein S lead to a resistance to activated protein C. Thus, all these changes in pregnancy favor
VTE.
After a VTE antecedent, thrombophilia is the most important individual risk factor for a new
thrombotic episode during gestation.
Besides VTE, recurrent abortions and other complications during pregnancy can be associated
to thrombophilia, particularly protein S deficiency and late complications.
A recent meta analysis has shown that a pregnant woman with thrombophilia has a greater
risk than non pregnant woman, particularly in the presence of homozygosis to Leiden Factor
V, to G20210A prothrombin gene mutation, in the presence of double heterozygosis for these
two mutations and in the presence of antithrombin III deficiency. All of these thrombophilias,
except MTHRF 677C>T gene mutation, even in homozygosis, bring about a statistically higher
risk of VTE during pregnancy (Robertson L 2006).
The predictive value for the risk of VTE relating pregnancy and thrombophilia is described on
table 1. (L. B. Pierangeli SS 2011).
Although, the absolut risk of VTE is low due to the low incidence of VTE itself. Even the risk
of VTE in more severe thrombophilia, such as antithrombin III deficiency and protein S
deficiency is low.
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Thrombophilia PPV*
FVL heterozygous state 1:500
prothrombin 20210 G>A heterozygous state 1:200
Double heterozygous state FVL + G20210A 4.6:100
Protein C deficiency 1:113
Antithrombin III deficiency 1:2.8
* PPV- positive predictive values
Table 1. Predictive values of hereditary thrombophilias and VTE.
Medical management of pregnant women with thrombophilia will depend on the risk analysis;
which may be complicated, because medical actions are based upon retrospective studies,
meta-analysis or case control studies.
The evaluation of other risk factors for VTE, personal and familial VTE history (first degree
relatives with VTE or arterial disease at age under fifty years old) should be taken into account
seriously.
Hereditary thrombophilia can be classified in thee risk categories (Fogerty AE 2009):
• High risk: FVL homozygosis, prothrombin 20210 G>A gene mutation in homozygosis,
double heterozygosis of FVL and prothrombin 20210 G>A, antithrombin III deficiency or
any thrombophilia with a previous VTE.
• Intermediate risk: thrombophilia not classified as high risk with family history of VTE.
• Low risk: heterozygosis for FVL, for prothrombin 20210 G>A, protein C and protein S
deficiency, lack of familial history or personal history for VTE.
As it is observed, personal or familial history of VTE has a strong weight on the VTE risk
implication.
A pregnant woman with thrombophilia that presents with VTE during pregnancy has to be
treated as a woman without thrombophilia with VTE. Treatment is based on heparin, partic‐
ularly low molecular weight heparin, with doses adjusted by maternal weight. Warfarin can
be exceptionally considered after the first trimester up till 34 weeks gestation. Fondaparinux
has already been used in pregnant patients who were unable to use other heparin.
Anticoagulation is recommended for six weeks after delivery for all women with hereditary
thrombophilia. During gestation, individual risk should be considered. Patients with high risk
should receive heparin prophylaxis as a treatment doses or intermediate dose. Patients with
intermediate risk should receive prophylactic heparin dose. Low risk patients should be
followed up carefully with strict recommendations to look for medical assistance in the event
of any symptoms that can be related to VTE.
Thrombophilia should be searched in any patient with familial history or personal history of
VTE or with the diagnosis of a hereditary thrombophilia on a first degree relative.
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A prospective study with 134 pregnant women heterozygous for FVL failed to show an
increase in the incidence of VTE. Thus, although being the most common hereditary throm‐
bophilia, its search is not to be indicated indiscriminately on every pregnant patient, nor
prophylaxis is to be offered to asymptomatic carriers (Dizon-Townson D 2005).
A recently published meta-analysis including ten prospective studies showed only a small
absolute risk for fetal death with demonstration of a small absolut risk with a smaller risk of
fetal death on heterozygous FVL (Rodger MA 2010).
It is suggested based on the experience of many studies that generalized search for thrombo‐
philia it is not indicated during pregnancy, except for patients with recent VTE event, or
punctual search of a familial or personal in one family member. History of VTE is the most
indicated event to look for thrombophilia.
Although thrombophilia are associated to an increase to the relative risk of complications
during pregnancy, including VTE, the absolut risk is still low.
3. Clinical interferences of thrombophilia in pregnancy
Pregnancy by itself is considered a hypercoagulation state. Likewise for diabetes, it is expected
to increase venous or arterial thromboembolism during pregnancy. The increase in estrogen
levels leads to increase in many of the coagulation factors. Thus, in the presence of a hereditary
or acquired thrombophilia a higher incidence of thrombotic events could be expected. Once a
thrombophilic state is already identified, than we can expect a higher chance of clinical and
obstetrical complications, except if prophylactic or therapeutic treatments are offered by caring
physicians and followed by patients.
Although this is a disseminated belief, systematic reviews fail to demonstrate such strong
relation. As stated above, only patients with a familial history of thrombosis or thrombophilia
should be investigated.
However, this is not universally agreed on the literature. For instance, a group of patients with
Leiden Factor V were compared to a group of absent mutation. It was observed that the group
with the mutation had no thromboembolic events, whereas the group without had 2,7%
thromboembolism (Dizon-Townson D 2005).
It has been also stated that even in relatives of probands who have no history of venous
thromboembolism (VTE) should not receive antithrombotic prophylaxis during pregnancy
because no difference was seen in the group with and without positive history of VTE prior
to pregnancy (Cordoba I 2012). With theses considerations, one must look for evidences
presented to date.
3.1. Thrombophilia and venous thromboembolism
Pregnancy is a clinical situation associated with increased risk of VTE, which increased from
twofold to fourfold when these women presented a positive family history of VTE (Bezemer
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ID 2009). Hereditary thrombophilia also increases the risk of VTE. However, the most
important for prevention of thrombosis in pregnant women with these additive risk factors is
the negative or positive history of previous VTE.
A meta-analysis and a review demonstrated increased risk of VTE in pregnant women with
thrombophilia without a family or a positive history of VTE (Robertson L 2006) (Biron-
Andreani C 2006). Heterozygosis for factor V Leiden and prothrombin 20210 G>A variant were
fortunately associated with the lower risk, as they were the most common inherited throm‐
bophilia. However, the homozygosis for these mutations was associated with the higher risk.
Deficiencies of natural anticoagulants were also associated to increased risk of VTE.
The incidence of VTE in the pregnancy is 1/1,000 deliveries, and the absolute risk of VTE in
thrombophilic women without a prior event or family history is in the range of 5-12/1,000
deliveries, except for homozygous carriers of the factor V Leiden or the prothrombin muta‐
tions, in whom the estimated baseline risk is about 4%.
Although the estimated risk of VTE in the presence of a positive family history of VTE and
inherited thrombophilia without a previous episode of VTE has been described, it is imprecise,
particularly for the rare thrombophilias (Friederich PW 1996).
Previous studies described higher risk of VTE in the presence of deficiencies of the anticoa‐
gulants, particularly antithrombin deficiency. However, methodological limitations could
have contributed to these conclusions (Conard J 1990). The recent studies showed similar risks,
even in double heterozygous for Leiden FV and prothrombin mutation (Tormene D 2001)
(Martinelli I 2008). The homozygosis for MTHFR C>T alone does not lead to an increased risk
of VTE in pregnant women (Robertson L 2006).
Women with thrombophilia without a family history presented a low risk of VTE. Because of
the absence of high-quality evidence measuring the effectiveness and safety of antithrombotic
agents in preventing VTE in patients with thrombophilia and a positive family history the
recommendations have limitations.
The most recent guidelines suggest antepartum prophylaxis with prophylactic or intermedi‐
ate-dose LMWH and postpartum prophylaxis for 6 weeks with prophylactic or intermediate-
dose LMWH or vitamin K antagonists targeted at INR 2.0 to 3.0 for pregnant women with no
prior history of VTE who are known to be homozygous for factor V Leiden or the prothrombin
20210 G>A mutation and have a positive family history for VTE (Bates SM and Physicians.
2012).
For patients with other thrombophilias without a previous history of VTE and who have a
positive family history for VTE it is indicated antepartum clinical vigilance and postpartum
prophylaxis for 6 weeks with prophylactic or intermediate dose LMWH or, in women who are
not protein C or S deficient, vitamin K antagonists targeted at INR 2.0 to 3.0 (Bates SM and
Physicians. 2012).
The same is indicated for pregnant women with no prior history of VTE who are known to be
homozygous for factor V Leiden or the prothrombin 20210 G>A mutation and who do not have
a positive family history for VTE (Bates SM and Physicians. 2012).
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Pregnant women with all other thrombophilias and no prior VTE who do not have a positive
family history for VTE, antepartum and postpartum clinical vigilance are indicated (Bates SM
and Physicians. 2012).
3.2. Thrombophilia and arterial vascular accidents in pregnancy
Stroke in pregnancy is one of the main causes of maternal death and pregnancy and puerpe‐
rium are known to increase its occurrence. The incidence of stroke is not precisely known and
there is a wide variation among reports across the world, ranging from 1.5 to 69 per 100
thousand pregnancies (Jaigobin C 2000) (Scott CA 2012). Stroke accounts for 2.2% of all deaths
in women of reproductive age and most of these deaths occur during pregnancy (WHO, 2004).
Puerperium increases the risk of stroke 5-18-fold and cerebral thromboembolism carries a
mortality rate 3 times higher in pregnant women. Despite the epidemiological association,
stroke is considered a multifactorial disease, and genetic, environmental, vascular and
hormonal factors play a complex and integrated role. Multiple genes have been studied, and
even in the same individual, more than one polymorphism, acting in inflammatory, vascular
and thrombotic pathways can lead to stroke.
With increasing worldwide efforts and acknowledgement to know about the causes and lessen
the consequences of stroke, pregnant women seem to be a special population, not only because
of the greater mortality but also because of the perinatal implications.
Obstetrical associated conditions are chronic hypertension, preeclampsia and cesarean
delivery. However, most cases do not have predisposing factors and occur in apparently
healthy subjects. Some physiologic changes during pregnancy and puerperium can be
associated with an increased risk of stroke: increased circulating blood volume, increased
cardiac output, vascular wall fragility, and high levels of steroid hormones.
Preeclampsia seems to be a risk factor even for non-pregnancy associated ischemic stroke,
which means that women who had preeclampsia have an increased risk of, is when non-
pregnant (Brown DW 2006). Non-obstetric risk factors include thrombophilia (inherited and
acquired) migraine, smoking, advanced maternal age, diabetes, sickle cell disease, autoim‐
mune conditions, and severe hypotension (Scott CA 2012).
Stroke in pregnancy and puerperium has three major clinical syndromes: ischemic stroke (IS),
intracranial hemorrhage (ICH) and cerebral venous thrombosis (CVT). It is the most frequent
presentation and CVT is rare. Maternal mortality can be as high as 50% for ICH and 20-25%
overall (Nomura ML 2012) (Scott CA 2012).
There are few studies addressing the role of thrombophilia in stroke occurring during
pregnancy or puerperium. We will focus mainly in thrombotic and ischemic stroke, since
hemorrhagic stroke has different pathogenic mechanisms in pregnancy, mainly related to
rupture of undiagnosed intracranial aneurysms and complications of eclampsia.
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3.2.1. Inherited thrombophilia
Inherited thrombophilias can be found in up to 11 % of patients with stroke (Bushnell CD
2000). In this systematic review, no association was found between factor V Leiden and IS, but
a slight increase in the odds ratio for prothrombin gene mutation was found (1.4; 95% CI
1.03-1.9).
A study by Voetsch (Voetsch B 2000) among 167 patients with ischemic stroke and did not find
an association with inherited thrombophilia, except in cerebral venous thrombosis, where
prothrombin gene mutation was more prevalent. For the small group of patients of African
origin, homozygosis for MTHFR 677C>T might have a potential role. Interestingly, patients
with CVT were all in use of oral contraceptives or in the puerperium.
Hankey (Hankey GJ 2001) tested 219 patients with ischemic stroke for inherited thrombophilia
in a case-control study and did not find a significant association (prevalence of 14.7% in stroke
patients and 11.7% in control subjects) between any thrombophilia or combination of throm‐
bophilias and IS, and the authors conclude that routine testing is not recommended in the
majority of patients.
Kim & Becker (Kim RJ 2003) performed a meta-analysis of the association between some
inherited thrombophilias and ischemic stroke and factor V, prothrombin, and homocysteine
metabolism were found to modestly increase the risk in young women.
Weber & Busch (Weber R 2005) performed a cost analysis of screening for inherited thrombo‐
philias in patients with IS of unknown cause and concluded that screening was of questionable
value, with the exception of antiphospholipid antibodies in younger patients.
Corod-Artal et al (Carod-Artal FJ 2005) screened 130 young patients with stroke, and only
protein S deficiency was found to be associated with stroke of unknown cause in young
subjects, but in this subpopulation 31% were oral contraceptive users.
Hamzi et al (Hamzi K 2011) performed the largest meta-analysis to date regarding possible
genes associated with ischemic stroke, with more than 150 thousand subjects included. They
found that MTHFR 677C>T, factor V Leiden, 20210 G>A prothrombin and ACE I/D polymor‐
phism had significant, although very modest, associations with IS. However, the authors did
not specify results in selected populations, such as pregnant women.
Haeusler et al (Haeusler KG 2012) reported an increased prevalence of factor VII polymor‐
phisms and factor V Leiden (although not significant) in patients with cryptogenic (unknown
cause) stroke.
All studies reported might have biases, such as selection of high-risk patients, and there is a
lack of controlled, prospective studies in pregnant women. Recommendations for routine
screening of inherited thrombophilias in the setting of stroke in pregnant or postpartum
women cannot be made at present, since pregnancy itself might be the most important risk
factor.
Inherited thrombophilia might play a role when associated with other conditions, acting
synergistically or increasing the odds of other risk factors, such as puerperium (particularly
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in CVT), preeclampsia/eclampsia, oral contraceptive use and acquired thrombophilias, such
as sickle cell disease.
3.2.2. Acquired thrombophilia
Acquired thrombophilia is a condition known to be associated with stroke. Transient cerebral
ischemia and stroke (including CVT) are clinical manifestations of antiphospholipid syndrome
(APS), but in order to establish the diagnosis a laboratory criteria must also be present, which
might be detection in the plasma of lupus anticoagulant, or anticardiolipin antibodies (IgG or
IgM) or anti-beta2-glycoprotein (IgG or IgM), in at least two occasions, 12 weeks apart, and
according to specific standard laboratory guidelines (Miyakis S 2006). The association between
IS and APS (primary and lupus-associated) is well established in case-control studies, and even
in unselected populations this association seems strong (Bushnell CD 2000).
Patients with previous cerebrovascular events who met criteria for APS should have anti-
thrombosis prophylaxis prescribed when pregnant, with non-fractioned or low-molecular
weight heparin. Prophylaxis should be extended into 6 weeks postpartum also. Aspirin can
also be added, particularly in the acute phase of an IS.
Patients with APS and previous cerebrovascular events have an increased recurrence risk of
IS, and preeclampsia seems to be an additional risk factor (Fischer-Betz R 2012).
Other acquired thrombophilias or thrombophilic status can potentially increase the risk of
stroke in pregnancy and puerperium, including sickle cell disease, nephrotic syndrome,
dehydration or severe hypovolemic status, and careful attention must be paid in this situations.
4. Thrombophilia and pregnancy complications
Adverse pregnancy outcome are not infrequent in general population. Pregnancy complica‐
tions include miscarriage, fetal loss, preeclampsia, fetal growth restriction, and placental
abruption.
The association between inherited thrombophilic disorders and miscarriage, late fetal loss or
severe preeclampsia has been described in various studies (Robertson L 2006) (v. d. Coppens
M 2006) (Rodger MA 2010).
However, there is a high uncertainty about these associations, particularly for the less preva‐
lent thrombophilia (Robertson L 2006). A meta-analysis including only prospective cohort
studies showed only association between factor V Leiden and pregnancy loss, but not with
other thrombophilias (Rodger MA 2010).
One randomized trial described increased live birth rate in women with factor V Leiden, the
prothrombin gene mutation, or protein S deficiency using enoxaparin when compared with
low-dose aspirin alone (Gris et al s et al), but the methodology was limited.
The results of other studies do not provide evidence that LMWH improves pregnancy outcome
in women with inherited thrombophilia and recurrent pregnancy loss (F. N. Coppens M 2007).
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Based on these findings the guidelines do not recommend screening for inherited thrombo‐
philia for women with a history of pregnancy complications. There is no indication of antith‐
rombotic prophylaxis for women with inherited thrombophilia and a history of pregnancy
complications.
The results of two studies that address this issue, Heparin for Pregnant Women with Throm‐
bophilia [NCT01019655] and TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
[NCT00967382] are awaited with interest.
4.1. Thrombophilia and recurrent pregnancy loss
Pregnancy loss in humans occurs in up to 75% of fertilized ova and 15% of well-confirmed
pregnancies (Boklage 1990) and recurrent pregnancy losses (RPL) affect 2–5% of women in
reproductive age (Hatasaka 1994). RPL is usually defined as the loss of three or more consec‐
utive pregnancies before 20 weeks of gestation or with fetal weights less than 500 grams. Within
this definition is a large and heterogeneous group of patients with many different causes of
miscarriage. RPL frequency increases up to 5% when clinicians define RPL as two or more
losses of pregnancy (Hogge 2003). In addition, epidemiological investigations have demon‐
strated that the frequency of subsequent pregnancy loss is 24% after two pregnancy losses,
30% after three and 40% after four successive pregnancy losses (Regan 1989). Additionally,
recurrent risk for RPL may increase up to 50 percent even after six losses (Poland B 1977).
Recurrent abortion involves more than 500,000 women in the United States per year (Bick
2000). Within the past ten years interest in correlations between thrombophilia and complica‐
tions of pregnancy has remarkably increased. Thrombotic processes may also be involved in
other serious obstetric complications, such as pre-eclampsia, intrauterine growth retardation
and placental abruption by impairment of placental perfusion. Pregnancy itself induces a
physiological hyper-coagulation state (Bick 2000) (Clark P 1998) (Stirling Y 1984) that might
be aggravated by inherited or acquired thrombophilia. Results of studies on pregnancy
complications in women with thrombophilia have been conflicting. This heterogeneous group
of disorders results in increased venous and arterial thrombosis. Some thrombophilic states in
RPL may be acquired such as antiphospholipid syndrome (APS) or heritable.
4.1.1. Acquired thrombophilia
Several studies have reported the presence of various autoantibodies in patients with RPL
(Roussev RG 1996). However, only the antiphospholipid antibodies (APL) have been clearly
associated to recurrent pregnancy losses both in patients with a known autoimmune disease,
as APS or systemic lupus erythematous (SLE), and in the general population.
APL were thought to be directed against negatively charged phospholipids, but it has been
shown that they are often directed against a protein cofactor, called beta 2 glycoprotein 1, that
assists antibody association with the phospholipid (McNeil HP 1990). APL has been associated
with thrombotic complications: some are systemic and some are pregnancy specific—sponta‐
neous abortion, stillbirth, intrauterine growth retardation, and preeclampsia (Harris 1986).
Diagnosis of this syndrome requires at least one of each clinical and laboratory criterion
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(ACOG 2005). Clinical criteria are: one or more confirmed episode of vascular thrombosis of
any type (venous, arterial, small vessel) and/or pregnancy complications (three or more
consecutive spontaneous pregnancy losses at less than 10 weeks of 
gestation, one or more fetal deaths at greater than 10 weeks of gestation, one or more preterm
births at less than 34 weeks of gestation secondary to severe 
preeclampsia or placental insufficiency). Laboratory criteria are: positive plasma levels of
anticardiolipin antibodies of the IgG or IgM isotope at medium to high levels and/or positive
plasma levels of lupus anticoagulant. Testing must be positive on two or more occasions, 12
weeks or more apart (Miyakis S 2006).
The APS is the autoimmune disease most commonly associated with RPL (Rai RS 1995) to as
low as 15% (Empson M 2002) and the presence of antiphospholipid antibodies is a major risk
factor for an adverse pregnancy outcome (Out HJ 1992).
There is still controversy over the timing (early or late) of pregnancy loss more closely related
with aPL. A retrospective study in a group of 366 women with recurrent pregnancy losses
compared the type of prior pregnancy loss between women with and without APL (Oshiro et
al, 1996). A total of 79 women included in the study tested positive for APL, while 290 did not.
The rate of prior early pregnancy loss was similar in both groups (>80%). However, those
patients with APL had 50% of prior late pregnancy losses compared with <25% late pregnancy
loss rate in women without APL. The specificity of late pregnancy loss for the presence of APL
was 76% compared with only 6% for two or more early pregnancy losses, thus suggesting that
late pregnancy loss is the most frequent type of loss associated with APS. Other studies have
found that most of the APL-related pregnancy losses were biochemical pregnancy losses or
early pregnancy losses in nature (Parazzini F 1991) (MacLean MA 1994) (Yetman DL 1996).
Experimental data using APS animal models further support the evidence that any type of
pregnancy loss (including preimplantation embryos), but mainly embryo reabsorption, may
be associated with APL (Ziporen L 1998).
The association of APL with recurrent pregnancy losses in patients with SLE and the APS
suggests a causative role but, by no means, it does prove it. The major pregnancy-related target
for APL is the placenta and utero-placental insufficiency is often attributed to vasculopathy of
the terminal spiral arteries that nourish the placenta intervillous space. These vessels had
smaller diameter and showed intimal lawyer thickening, fibrinoid necrosis, and intraluminal
thrombosis (De Wolf et al, 1982). In other cases, the infarcted region may show villous
congestion and hemorrhage and early trophoblastic necrosis (Bendon RW 1987). In addition
to placental infarction and thrombosis, perivillous fibrin deposition and evidence of decidua
vascular atherosis, indicative of spiral artery vasculopathy, are seen in some APS cases
(Gharavi AE 2001).
The mechanisms by which aPL cause the above described changes are not completely under‐
stood and several hypotheses have been proposed. The earliest one is eicosanoid balance
alteration mediated by aPL. Inhibition of endothelial cell production of PGI2 (a potent inhibitor
of platelet aggregation and vasodilator) and enhancement of placental TXA2 production by
plasma from aPL-positive women have been demonstrated by some investigators (Carreras
LO 1981) (Schorer AE 1992). Another possible mechanism for thrombosis in APS is the cross-
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reactivity between APL and glycosaminoglycans, a family of heparin-like substances related
with the non-thrombotic properties of the vascular endothelium. The inhibition of this function
by APL may in part explain the thrombosis associated with them (Chamley LW 1993).
Additionally, APL may interfere with the function of natural inhibitors of coagulation such as
placental anticoagulant proteins (PAP) and others. PAP is a group of four calcium-dependent
phospholipid-binding proteins that inhibit phospholipid- dependent steps of coagulation by
making phospholipid inaccessible to clothing factors (Walker JH 1992). The major component
of the PAP family is the PAP-1, also called annexin V, which is most abundant in the placenta.
Annexin V and aPL compete for phospholipids in coagulation assays (Sammaritano LR 1992).
It has been shown that distribution of annexin V over the intervillous surface was significantly
lower in patients with APS that in women with recurrent pregnancy losses (Rand JH 1994).
These findings suggest that reduced annexin V production and inhibition of its anticoagulant
function by aPL may play a role in pregnancy loss in APS patients.
However, other non-thrombotic mechanisms have been implicated, being interference with
the embryonic implantation the one that has received more attention. The APL have been
found to react directly with third trimester villous trophoblastic cells (Lyden TW 1992) (Di
Simone N 2000), prevent proliferation of trophoblast derived from choriocarcinoma cells
(Chamley LW 1993), inhibit in vitro chemotaxis and differentiation of villous trophoblast
isolated from third trimester placentae (Di Simone N 2000), decrease trophoblast invasion
(Sebire NJ 2002) (Bose P 2005), and inhibit extra-villous trophoblast differentiation (Quenby S
2005). Furthermore, APL can induce pregnancy loss in mice by impairing the embryonic
implantation capacity, likely because a direct interaction with the throphoectoderm cells
(Sthoeger ZM 1993).
Additionally, aPL may impair the placenta production of chorionic gonadotropin during the
early phases of pregnancy, thus determining the embryonic evolution (Shurtz-Swirski R
1993) and, in the mice model, APS is associated with a diminished secretion of interleukin-3,
positively related with pregnancy the pregnancy loss is prevented by in vitro administration
of recombinant interleukin-3 (Fishman P 1993).
Furthermore, the role of complement activation by the aPL has also received a great deal of
attention. Several studies have suggested that activation of the complement cascade is
necessary for aPL-mediated thrombophilia and fetal loss (G. G.-O. Pierangeli SS n.d.) (Holers
VM 2002). It was found that inhibition of the complement cascade in vivo, using the C3
convertase inhibitor complement receptor 1-related gene protein y (Crry)-Ig, blocks aPL-
induced fetal loss and growth retardation, and reversed aPL-mediated thrombosis (Holers VM
2002).
4.1.2. Inherited thrombophilia
In 1996 the first reports on an association between other forms of thrombophilia and recurrent
pregnancy loss were published (Preston FE 1996) (Rai RS 1995) (Sanson BJ, 1996). Since then
numerous case control studies investigating the impact of thrombophilia on pregnancy loss
have been conducted (Kupferminc MJ 1999) (Gris JC R.-N. S., 1997) (Grandone E 1997) (Younis
JS, 2000) (Pihusch R 2001) (Alonso A, 2002) (Rasmussen A, 2004). In most of these studies factor
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V Leiden (Factor V 1691 G>A), prothrombin 20210 G>A and the methylene tetrahydrofolate
gene 677 C>T variations were determined. Some studies also included other classical markers
of thrombophilia, such as antithrombin III, protein C and protein S deficiency and APL
(Kupferminc MJ 1999)(Kupferminc MJ, 1999) (Gris JC Q. I., 2000).
The normal coagulation pathway is pivotal for the pregnancy outcomes. Also any kind of
disorder in coagulation pathway may cause thrombophilia that may be the reason of placental
insufficiency and pregnancy loss (Reznikoff-Etievan MF, 2001). It has become clear that pro-
thrombotic changes are associated with a substantial proportion of these fetal losses. Throm‐
bophilic defects, including mutations in factor V Leiden and prothrombin 20210 G>A, and
deficiencies in protein C, protein S, and antithrombin III, have been reported in 49–65% of
women with pregnancy complications and in 18–22% of women with normal pregnancies (B.
1999) (Kupferminc MJ, 1999).
Therefore, the role of thrombophilias in RPL has generated a great deal of interest. This
heterogeneous group of disorders results in increased venous and arterial thrombosis.
Although some thrombophilic states in RPL may be acquired such as APS, most are heritable
such as hyperhomocyteinemia, activated protein C resistance, deficiencies in proteins C and
S, mutations in prothrombin, and mutations in antithrombin III. The three most known
common genetic markers for thrombophilia to predispose to venous thrombosis are; factor V
Leiden (FVL), methylenetetrahydrofolate reductase mutation (MTHFR 677 C>T) and pro‐
thrombin gene mutation. Thrombophilic disorders have generated considerable interest in the
field of RPL. Thrombophilia is an important predisposition to thrombosis due to a pro-
coagulant state. Several blood-clotting disorders are grouped under the term of thrombophilia.
Clinical studies suggest that the underlying pathophysiological mechanism is mediated via
hypercoagulation, leading to utero-placental insufficiency with resultant pregnancy loss. The
basis for the association between adverse fetal outcomes and heritable thrombophilias has
focused on the mechanisms of impaired placental development and function secondary to
venous or arterial thrombosis at the maternal–fetal interface (Aubard Y, 2000) (Cotter AM 2001)
(Jeanine F, 2010).
Mutation in the gene-encoding factor V results in a protein that is resistant to the effects of
activated protein C (aPC). The most common of a variety of mutations is at position 506 with
a glutamine substitution for arginine; this FV: R506Q mutation is called the factor V Leiden
mutation. The mutation results in a protein resistant to the effects of activated protein C (aPC).
The net result is increased the cleavage of prothrombin to thrombin, which causes excessive
coagulation.
The resistance to aPC has emerged as the commonest genetic cause of thromboembolism. It is
caused by FVL in 95% of cases. The risk of thrombosis is increased 5- to 10-fold in heterozygous
carriers of FVL, and 100-fold in homozygosis (Kovalevsky G, 2004).
Inherited decreased or absent antithrombin III activity will lead to increased thrombin
formation and clotting. Prothrombin gene mutation is signaled by a defect in clotting factor II
at position G20210A. The relative risk for thrombosis in patients with this mutation is two-fold
in heterozygotes.
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Individuals with hiperhomocisteinemia exhibit a deficiency of folate due to the presence of
the methylene tetrahydrofolate reductase mutation (MTHRF 677C>T C677 T). The thrombotic
risk is increased two-fold in homozygosis; and in the heterozygous state for Antithrombin III
deficiency, the risk is 20- to 50-fold.
Consistent with general thrombotic risk, carriage of combinations of two or more inherited
thrombophilic defects has particularly strong association with adverse pregnancy outcomes
(Lockwood C. J., 2002) (Preston FE, 1996). Considerable attention has been directed recently
toward a possible relationship between thrombophilias and certain pregnancy complications
other than venous thrombosis (De Santis M, 2006).
4.1.3. In vitro fertilization failures and thrombophilia
The known or purported causality of phospholipid antibodies and coagulation factors on
recurrent pregnancy loss long ago spilled over into the arena of conception with IVF or
more precisely, the lack of it.  Some have argued that without implantation to signal the
arrival  of  an  embryo,  it  would  be  improbable  for  serum  or  tissue-based  response  ele‐
ments  to  prevent  implantation.  Others  have  argued  that  the  effect  is  unrelated  to  the
embryo, but rather the negative impact is  at  the level of the endometrium. The Practice
Committee  of  the  American  Society  for  Reproductive  Medicine  released  a  Committee
Opinion in 1999, which it reviewed again in 2008, ‘‘Anti-phospholipid antibodies (APA) do
not affect IVF success’’ (Practice Committee of American Society for Reproductive Medi‐
cine. 2012). The review culled 16 peer-reviewed papers, of which 7 included appropriate
endpoints  and controls.  There  was  no  statistically  significant  impact  of  the  presence  of
phospholipid antibodies on IVF outcomes neither when studies were examined individual‐
ly nor when the data were aggregated in the 2,053 patients studied. The authors conclud‐
ed that ‘‘assessment of APA is not indicated among couples undergoing IVF. Therapy is
not justified on the basis of existing data.’’
A review was recently published on the topic of thrombophilias and IVF outcome (Di Nisio
M, 2011). The authors' initial search yielded 694 studies. Case reports, editorials, reviews, meta-
analyses, studies with inadequate outcomes, absence of thrombophilia/anti-phospholipid
antibodies, and more than one of the above was excluded and 33 (6,092 patients) were
ultimately analyzed. They report that twenty-nine studies (5,270 patients) assessed anti-
phospholipid antibodies in women treated with assisted reproductive techniques (ART). The
prevalence of antibodies in infertile patients varied from 0%–45%. When examining case-
control studies, the authors write ‘‘overall, the presence of one or more anti-phospholipid
antibodies was associated with a 3-fold higher risk of ART failure.’’ There was a significant
degree of heterogeneity across these case-control studies.
4.2. Thrombophilia and fetal growth restriction
Obstetricians have been very interested on the possible consequences of thrombophilia
because in face of an unexpected pregnancy event, such as fetal growth restriction not
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associated to preeclampsia or arterial hypertension, colagenosis as Systemic Lupus or any
other maternal identified disease. This has been the casa once many patients that would have
the profile for antiphospholipid syndrome showed no abnormal antibodies on their laboratory
workup. So, there would be another group of women that would have another type of
“coagulation disorder” that would have to be sorted out.
Considering the possibility that fibrin deposition on the maternal surface of the placenta may
impair gas exchanges and nutritional elements between mother and fetus, the model of a
thrombophilic induced placental insufficiency seems very attractive.
It has to be emphasized that most studies focus on the maternal aspect of maternal thrombosis
in thrombophilia and less is regarded on the obstetrical and fetal complications of thrombo‐
philia in pregnancy.
It has been shown by some authors that this association is found in case control study (Monari
F, 2012), where all thrombophilias evaluated had a greater incidence within patients with
history of fetal death and that Factor II 20210 G>A gene mutation had also a predictive value
for previous fetal deaths in this study population.
Others contest this association when placental infarction is evaluated in comparison to
abnormal placentation (Franco C 2011). In this study, no association was found between the
presence of thrombophilia and histological findings of infarction.
One of us (R.B., personal communication not published) have observed instances where
patients develop placental ultrasonography abnormal image - Grade II or III during second
trimester – (Grannum PA, 1979) together with fetal growth restriction that demonstrated true
catch up in fetal growth and sustained or regression in placental grade upon prophylactic low-
dose heparin and aspirin regimen. In two occasions patients showed to be Leiden Factor
heterozygous and Protein S deficiency.
One interesting study showed an increase in the frequency of patients with prothrombin gene
mutation associated to IUGR and abruptio placentae (Kupferminc MJ, Peri H, Zwang E, Yaron
Y, Wolman I, 2000).
Although randomized trial are still necessary to address the question whether treatment
should be advised for women with diagnosed hereditary thrombophilia to prevent adverse
pregnancy results, many authors agree that treatment ensures good results, like the one
reported by results Kosar (Kosar A 2011). The live birth rate for treated patients was only 62%,
even with treatment, which brings up de the consideration that this is really a high-risk
obstetrical population.
One group showed that the institution of low-molecular-weight heparin to women with
previous fetal growth restriction or pre eclampsia had a dramatic reduction on the recurrence
of these events on subsequent pregnancies (Kupferminc, 2011).
When reviewing the literature one must be careful with the conclusions offered because most
of the studies do not have a good enough large sample size to draw final conclusions.
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This is the case of the Australian study comparing pregnancy results of women with and
without inherited thrombophilia and positive pregnancy with pre eclampsia, fetal restriction,
fetal death or placental abruption. Groups comprised 115 women on each arm and no
difference on the frequency of thrombophilia in the group with and without adverse history.
Now we have to wonder that for instance, Leiden Factor V is expected in less than 2% of any
Caucasian population and 20210 G>A prothrombin gene mutation is even less frequent. A case
control study would have to add up at least 600 hundred woman on each arm to be able to
draw final conclusions.
A large cohort study of nulliparous women as performed where the results of inherited
thrombophilia was blind to caring physicians and only a strong association of 20210 G>A
prothrombin gene mutation was found to adverse results of their pregnancies (pre eclampsia,
fetal death, fetal restriction, placenta abruption). None of the other thrombophilia showed
association to any of these events in this asymptomatic population (Said, 2010).
When we look in the literature on acquired thrombophilia and fetal growth restriction, there
is greater agreement that there is a relation between them.
4.3. Thrombophilia and preeclampsia
Preeclampsia is a leading cause of maternal-fetal morbidity and mortality. It accounts for a
significant fraction of maternal deaths in developed and underdeveloped countries. Pree‐
clampsia is one of the most researched diseases in medicine, and so far several aspects of its
pathophysiology have been elucidated. However, a major concept that prevails among the
most important studies is that preeclampsia is a multifactorial disease.
One of the most controversial aspects is the role of acquired and inherited thrombophilia in
the development of preeclampsia. In this chapter, we present a review on the studies about
thrombophilia and preeclampsia, with a critical standing point and future perspectives on this
issue.
How thrombophilia might act as cause or contributor in preeclampsia? Thrombophilias may
act as co-factor in decreasing placental function through vascular thrombosis and also may
regulate inflammatory pathways and increase intravascular coagulation. Alltogether with
other contributors these features may trigger endothelial dysfunction and lead to the clinical
and laboratorial picture of preeclampsia (Kupferminc., 2003).
4.3.1. Inherited thrombophilias
Among inherited thrombophilias, the most studied are factor V Leiden mutation, 20210 G>A
prothrombin mutation, MTHRF 677C>T, protein C deficiency, protein S deficiency and
activated protein C resistance.
There are conflicting results regarding the association between inherited thrombophilias and
preeclampsia. This might be due to several factors: small sample sizes, poor methodological
quality, retrospective nature of most studies and heterogeneity in the prevalence of thrombo‐
philia in different populations.
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Initial reports showed a marked increase in the prevalence of thrombophilic mutations in
women with preeclampsia compared to women with uneventful pregnancies, with figures of
40% to 72% for at least one mutation (Stella CL, 2006) (Kupferminc MJ, 1999). These studies
were in most part case-control and included women with late and early-onset, mild and severe
preeclampsia, as also HELLP syndrome and eclampsia.
Despite these convincing evidences, several studies further did not confirm such a strong
association (Rodger, 2007).
Kosmas et al (Kosmas, 2003) reported a meta-analysis of more than 5,000 women among 19
studies. For the studies published until 2000, an association was found between factor V Leiden
and preeclampsia, however, for the studies published in 2001-2002 this association was not
confirmed.
Dizon-Towson et al (Dizon-Townson D, 2005) also found no association between factor V
Leiden and prothrombin mutations with preeclampsia, and this was a multi-center, prospec‐
tive study.
Another prospective study (Said, 2010) involving 2034 women did not find significant
associations between any inherited thrombophilia and preeclampsia and the authors conclud‐
ed that the majority of women with inherited thrombophilia have normal pregnancy outcomes.
Alfirevic et al. (Alfirevic, 2002) reported the first systematic review of the association between
maternal thrombophilia and preeclampsia, and factor V Leiden mutation (heterozygous),
20210 G>A prothrombin mutation (heterozygous), MTHFR 677C>T (homozygous), protein C
deficiency, protein S deficiency and activated protein C resistance were more prevalent among
women with preeclampsia.
In a systematic review performed by Robertson et al. (Robertson L, 2006), the odds ratios for
several genetic mutations (factor V Leiden, prothrombin mutation, MTHFR 677C>T and
protein S) ranged from 1.37 to 3.49, with evidence of heterogeneity among some studies.
In a systematic review and meta-analysis, Rodger et al. (Rodger MA, 2010) failed to show a
significant association between factor V Leiden and prothrombin gene mutation. This review
included ten prospective cohort studies and more than twenty thousand patients.
Combined thrombophilias (being carrier of more than one mutation) might have a stronger
association with early-onset, severe preeclampsia and HELLP syndrome, however conclusive
and solid evidence is also lacking.
The  American  College  of  Obstetricians  and  Gynecologists  (Lockwood  C,  Wendel  G;
Committee  on  Practice  Bulletins—  Obstetrics.,  2011)  stated  that  the  evidence  is  insuffi‐
cient to conclude that inherited thrombophilia increases the occurrence of preeclampsia and
therefore do not recommend screening and treatment for thrombophilia in women with
previous preeclampsia.
Lockwood (Lockwood C., 2010) also cautioned against screening and treatment for inherited
thrombophilias, unless in the setting of a clinical trial. The author argues that methodological
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quality of the positive associations is questionable, that these associations are modest (3-fold
increase) and that large prospective cohort studies did not show a consistent association.
In summary, the most recent evidence points to a weak association between preeclampsia and
inherited thrombophilias. Even this evidence derives from small studies, with possible
selection and report biases. The recent evidence also discourages treatment with heparin based
on a diagnosis of inherited thrombophilia.
4.3.2. Acquired thrombophilia
Antiphospholipid antibodies are more frequently encountered in patients with preeclampsia,
and in this setting they might be a modulator of the severity of the disease rather than a direct
cause.
The Sydney Consensus Statement on Investigational Classification Criteria for the Antiphos‐
pholipid Syndrome (Miyakis S, 2006) included eclampsia or severe preeclampsia leading to
preterm delivery prior to the 34th week as clinical criteria. To establish the diagnosis of
antiphospholipid syndrome (APS) a laboratory criteria must also be present, which might be
detection in the plasma of lupus anticoagulant, or anticardiolipin antibodies (IgG or IgM) or
anti-beta2-glycoprotein (IgG or IgM), in at least two occasions, 12 weeks apart, and according
to specific standard laboratory guidelines.
Do Prado et al (do Prado AD, 2010) performed a systematic review on the association between
preeclampsia and anticardiolipin antibodies. The authors found a significant association with
an odds ratio of 11.15 for severe preeclampsia and 2.86 for preeclampsia.
Abou-Nassar et al. (Abou-Nassar K, 2011) Published a systematic review of antiphospholipid
antibodies and preeclampsia and found an inconsistent association, detected only in case-
control studies but not in cohort studies, and of lower magnitude.
Although controversial, recent evidence suggests that treatment with heparin and low-dose
aspirin in order to reduce recurrence risk is warranted in this situation, with overall pregnancy
success rates of more than 70% (Ernest JM, 2011) (Lockwood C., 2010).
It must also be noted that women with APS are at greater risk of thromboembolism, and
anticoagulation should be prescribed for this purpose also.
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